

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/22-23/BSE-72

Date 14-08-2022

To

Department of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Outcome of Board Meeting pursuant to Reg. 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on 14th August, 2022 has considered and approved the Un-Audited Consolidated & Standalone Financial Results of the Company for the quarter ended 30th June, 2022 along with the limited review report thereon issued by M/s Raman Wadhwa & Co., Statutory Auditors of the Company.

The Board meeting was commenced at 04:00 P.M. and concluded at 05:45 P.M.

Kindly take the above on your record.

Yours Faithfully,

For **ANG Lifesciences India Limited**

Renu Kaur
Company Secretary
M. No. A62402



Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.


Dated.

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Unaudited Financial Results of ANG Lifesciences India Limited ("Holding Company") and its wholly owned subsidiary (the Holding and its wholly owned subsidiary together referred to as "the Group") (refer annexure-I for the list of subsidiary included in the Statement) for the quarter ended 30th June, 2022 ("the statement") attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations") including relevant circulars issued by the SEBI from time to time.
2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in





Raman Wadhwa & Co.



CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated.

scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.
5. The Statement includes the result of the following entities:-
Mansa Print & Publishers Limited
6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Raman Wadhwa & Co.
Chartered Accounts



(Ishant Sharma)
Partner

Res No. 012036N

Place: Amritsar

Date: 14 August 2022

M.No. 527055

UDIN: 22527055 A0ZWFV9529

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated unaudited results for the quarter ended 30 June 2022

(₹ in lakhs except per share data)

Particulars	Quarter ended 30 June 2022	Quarter ended 31 March 2022	Quarter ended 30 June 2021	Year ended 31 March 2022
	(Unaudited)	refer note 4 (Audited)	(Unaudited)	(Audited)
I Revenue from operations	7,370.75	9,537.77	11,987.20	35,430.17
II Other income	8.83	56.94	7.66	90.13
III Total revenue (I+II)	7,379.58	9,594.71	11,994.86	35,520.30
IV Expenses				
Cost of materials consumed	4,749.41	6,801.46	7,039.84	23,465.10
Changes in inventories of finished goods and work-in-progress	(44.66)	(86.01)	351.99	(666.89)
Employee benefits expense	619.75	575.98	446.84	2,129.01
Finance costs	344.47	391.77	136.62	890.52
Depreciation and amortisation expenses	208.96	260.61	53.63	587.52
Other expenses	844.91	972.85	1,200.57	3,764.99
Total expenses (IV)	6,722.75	8,916.66	9,229.50	30,170.25
V Profit before exceptional items and tax (III-IV)	656.73	678.05	2,765.37	5,350.05
VI Exceptional items	-	-	-	-
VII Profit before tax (V-VI)	656.73	678.05	2,765.37	5,350.05
Tax expense				
(1) Current tax	236.31	221.50	700.60	1,346.50
(2) Deferred tax	71.04	(68.59)	61.65	(28.10)
VIII Total tax expense (1+2)	307.35	152.90	762.25	1,318.40
IX Profit for the period (VII-VIII)	349.38	525.15	2,003.12	4,031.65
X Other comprehensive income:				
Items that will not be reclassified to profit or (loss)	85.94	14.23	1.21	27.98
Income tax relating to items that will not be reclassified to profit or loss	(21.63)	(4.88)	(0.30)	(7.04)
XI Total comprehensive income (IX+X)	413.69	534.50	2,004.02	4,052.59
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,036.66	1,036.66	518.33	1,036.66
XIII Other equity				7,340.25
XIV Earnings per equity share (of ₹ 10/- each)				
a) Basic	3.99	5.16	38.66	39.09
b) Diluted	3.99	5.16	38.66	39.09

See accompanying notes to the financial results.

For ANG Lifesciences India Limited

Rajesh Gupta
Managing Director
DIN 01423407



Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.

E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated.

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended 30th June, 2022 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



CA. Ishant Sharma
B.Com, FCA

M: 97805-99974



Raman Wadhwa & Co.



CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.


E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Raman Wadhwa & Co.
Chartered Accounts



(Ishant Sharma)
Partner

Rsg No. 012036N

Place: Amritsar

Date: 14 August 2022

M.No. 527055

UDIN: 22527055 AOZWFV9529

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of standalone unaudited results for the quarter ended 30 June 2022

(₹ in lakhs except per share data)


Particulars	Quarter ended 30 June 2022	Quarter ended 31 March 2022	Quarter ended 30 June 2021	Year ended 31 March 2022
	(Unaudited)	refer note 4 (Audited)	(Unaudited)	(Audited)
I Revenue from operations	7,155.63	9,586.99	11,799.61	34,866.94
II Other income	12.34	62.33	7.92	95.15
III Total revenue (I+II)	7,167.97	9,649.32	11,807.52	34,962.09
IV Expenses				
Cost of materials consumed	4,848.69	6,956.66	6,955.15	23,448.55
Changes in inventories of finished goods and work-in-progress	(148.50)	(9.05)	398.02	(447.47)
Employee benefits expense	548.64	501.71	392.36	1,832.47
Finance costs	317.45	350.64	133.67	785.00
Depreciation and amortisation expenses	188.09	237.04	36.47	512.03
Other expenses	778.75	925.78	1,141.79	3,525.15
Total expenses (IV)	6,533.12	8,962.78	9,057.47	29,655.73
V Profit before exceptional items and tax (III-IV)	634.85	686.54	2,750.06	5,306.36
VI Exceptional items	-	-	-	-
VII Profit before tax (V-VI)	634.85	686.54	2,750.06	5,306.36
Tax expense				
(1) Current tax	236.31	221.50	700.60	1,346.50
(2) Deferred tax	64.24	(63.15)	(5.81)	(11.44)
VIII Total tax expense (1+2)	300.55	158.35	694.79	1,335.07
IX Profit for the period (VII-VIII)	334.30	528.19	2,055.27	3,971.30
X Other comprehensive income:				
Items that will not be reclassified to profit or (loss)	85.60	14.23	1.21	27.98
Income tax relating to items that will not be reclassified to profit or loss	(21.54)	(4.88)	(0.30)	(7.04)
XI Total comprehensive income (IX+X)	398.36	537.54	2,056.18	3,992.24
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,036.66	1,036.66	518.33	1,036.66
XIII Other equity				7,311.45
XIV Earnings per equity share (of ₹ 10/- each)				
a) Basic	3.84	5.19	39.67	38.51
b) Diluted	3.84	5.19	39.67	38.51

See accompanying notes to the financial results.

For ANG Lifesciences India Limited

Rajesh Gupta
Managing Director
DIN 01423407

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter Ended		Year Ended	
		30 June	31 March	30 June	31 March
		(Unaudited) 2022	(Audited) 2022	(Unaudited) 2021	(Audited) 2022
1	Segment revenue				
	a) Pharmaceuticals	7,155.63	9,586.99	11,799.61	34,866.94
	b) Printing and packagings	985.44	713.09	428.90	2,189.68
	Total	8,141.07	10,300.08	12,228.50	37,056.62
	Less: Inter segment revenue	770.31	762.31	241.30	1,626.45
	Revenue from operations	7,370.75	9,537.77	11,987.20	35,430.17
2	Segment results (profit before tax and finance cost from each segment)				
	a) Pharmaceuticals	950.32	1,030.04	2,880.91	6,084.22
	b) Printing and packagings	50.89	39.79	21.09	156.35
	Total	1,001.20	1,069.83	2,901.99	6,240.57
	Less: Finance costs	344.47	391.77	136.62	890.52
	Profit before tax	656.73	678.06	2,765.37	5,350.05
	Particulars			As at 30 June 2022	As at 31 March 2022
3	Segment Assets				
	a) Pharmaceuticals			27,218.46	26,511.12
	b) Printing and packagings			2,170.81	2,591.92
	Total Segment assets			29,389.27	29,103.04
4	Segment liabilities				
	a) Pharmaceuticals			18,000.05	18,200.11
	b) Printing and packagings			2,598.62	2,526.01
	Total Segment liabilities			20,598.67	20,726.12



For ANG Lifesciences India Limited

Rajesh Gupta
Managing Director
DIN 01423407

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.

2. The standalone and consolidated financial results for the quarter ended 30 June 2022 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 August 2022. The statutory auditors of the Company have expressed an unmodified opinion on these results.

3. The above results of ANG Lifesciences India Limited ('the Company' or 'the Holding Company') and its wholly owned subsidiary (the Holding Company and its Wholly Owned Subsidiary together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 05 July 2016 and other accounting principles generally accepted in India. Consequently, financial results for the quarter ended 30 June 2022 have been aligned to comply with Ind AS requirements to make them comparable with current periods.

4. Figures for the standalone and consolidated financial results for the quarter ended 31 March 2022 are the balancing audited figures of the full financial year and the published year to date figures upto the third quarter of the year ended 31 March 2022 which were subjected to limited review by the statutory auditors of the Company.

5. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.

6. Previous period figures have been re-grouped / reclassified wherever necessary to conform to current period's classification in order to comply with the requirements of the amended Schedule III of the Companies Act, 2013 effective from 01 April 2021.

7. The Board of Directors of the Company in its meeting held on 30 May 2022, have approved the issue of bonus equity shares in the proportion of 1 (One) equity share of Rs. 10/- each for every 4 (four) equity shares of Rs. 10/- each held by the shareholders of the Company as on the record date.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited


Managing Director
DIN 01423407
Place: Amritsar
Date: 14 August 2022